SFM
CARM

Signet Financial Management’s Carisma Therapeutics CARM Stock Holding History

Signet Financial Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-500
Closed -$11K – 254
2019
Q3 		$11K Buy
+500
New +$11.7K ﹤0.01% 237

Other funds holding CARM

TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Signet Financial Management's CARM Position: Q4 2019 in Review

Signet Financial Management sold out of Carisma Therapeutics (CARM) in Q4 2019, closing a stake of 500 shares — an estimated $11K sold.

Signet Financial Management first reported a position in CARM in Q3 2019 and held it in 1 quarter. The position peaked at $11K in Q3 2019. 46 funds tracked by Wall St. Rank hold CARM as of Q4 2019.

  • Signet Financial Management reported no remaining Carisma Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Signet Financial Management sold 500 Carisma Therapeutics shares in Q4 2019, an estimated $11K.
  • Signet Financial Management first reported a position in Carisma Therapeutics in Q3 2019 and held it in 1 quarter.
  • Signet Financial Management's Carisma Therapeutics position peaked at $11K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2019.

Based on Signet Financial Management's 13F filing for Q4 2019, filed 23 Jan 2020.